As RIPK3 is necessary for necroptosis – and as necroptosis is considered to be inherently inflammatory – researchers have suggested that RIPK3 or MLKL should be targeted to decrease atherosclerosis severity in the clinical setting (Zhe-Wei et al., 2018; Coornaert et al., 2018). Here, RIPK3 is linked to atherosclerosis.